<DOC>
	<DOCNO>NCT00980304</DOCNO>
	<brief_summary>It phase II , multicenter , open label clinical trial . Only relapse DLBCL patient 1st line induction treatment 6~8 cycle RCHOP-like chemo enrol receive 3 cycle RICE salvage therapy . After treatment patient follow 2 year .</brief_summary>
	<brief_title>R Retreatment 1st Relapsed DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Relapsed DLBCL patient receive 6 8 cycle RCHOPlike chemotherapy 1st line induction treatment . 2 . Disease relapse early 6 month prior induction treatment . 3 . Confirmed CD20 positivity lymphoma time diagnosis ( prior induction therapy ) 4 . ECOG performance status 0 , 1 2 time inclusion ( see Appendix IV ) 5 . Known IPI time diagnosis ( prior induction therapy ) 6 . Age ≥18 year &lt; 65 7 . Life expectancy &gt; 3 month 8 . Be willing able comply protocol duration study 9 . Agree use effective contraception entire treatment period 12 month thereafter 10 . Patient 's write informed consent 1 . More one prior chemoimmunotherapy regimen . 2 . Histologies DLBCL accord WHO/REAL classification 3 . History malignancy squamous cell carcinoma , basal cell carcinoma skin , surgically treat malignant melanoma carcinoma situ cervix within last 5 year . 4 . Major surgery , diagnostic surgery , within last 4 week . 5 . Evidence CNS involvement patient 6 . Unacceptable hematologic status baseline prior study start value list : WBC : &lt; 3 x 109/L ; absolute neutrophil count ( segment + band ) &lt; 1.5 x 109/L ; platelet : &lt; 100 x109/L 7 . Abnormal liver function test prior study start value list : serum bilirubin &gt; 2 mg/dL ( 30 mmol/L ) ; ALAT ASAT &gt; 2.5 x upper limit normal range ; Abnormal renal function ( serum creatinine &gt; 150 μmol/L ) . 8 . HIVpositive patient . 9 . Contraindication investigational medication 10 . Active viral hepatitis , specifically HBV HCV infection 11 . Serious underlie medical condition , ( e.g . ongoing infection , uncontrolled diabetes mellitus , severe cardiac dysfunction angina , gastric ulcer , active autoimmune disease ) 12 . Life expectancy &lt; 3 month 13 . Treatment within clinical trial within 30 day prior trial entry 14 . Women breast feeding , use effective contraception , pregnant 15 . Patients tutelage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Diffuse large B cell lymphoma</keyword>
</DOC>